EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
- Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
- Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
- Bayer transforms pharma business through breakthrough innovation in healthcare
- Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
Research & Development
- Obesity, impaired metabolic health and COVID-19
- COVID-19 has multiple faces
- Metformin use reduces risk of death for patients with COVID-19 and diabetes
- New England Journal of Medicine publishes COVID-19 treatment trial results
- Scientists identify 'immune cop' that detects SARS-CoV-2
- New findings help explain how COVID-19 overpowers the immune system
- New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
- FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2